Business Standard

Remdesivir reduces hospital stay, doesn't show benefit in mortality: AIIMS

AIIMS Director Dr Randeep Guleria explained the ways in which Covid-19 patients are being treated

coronavirus
Premium

(FILE PIC) Health workers collect swab samples from people for Covid-19 tests in New Delhi | Photo: PTI

ANI New Delhi
Remdesivir helps decrease hospital stay but the benefits don't reflect as far as death or mortality is concerned, All India Institute of Medical Sciences (AIIMS) New Delhi Director Dr Randeep Guleria said on Friday.

"There is no definite anti-viral drug which has been proved as far as Covid-19 is concerned. A lot of research is going on. There are some anti-viral drugs which are being used, one of them is 'Remdesivir' that is being made by a company from the US. Data suggests that it helps to decrease hospital stay but it doesn't show benefit as far as death or

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in